Linked Life Data

16566282

Source:http://linkedlifedata.com/resource/pubmed/id/16566282

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2 Suppl
pubmed:dateCreated
2006-3-28
pubmed:abstractText
When first approved in December 2002, 15% azelaic acid (AzA) gel represented a significant advance over the available 20% AzA cream. Although a smaller amount of AzA was present in the new formulation, the gel medium provided a highly effective system for delivering the active ingredient, thus providing more effective treatment. This article explores the nature of these 2 vehicles and highlights the importance of the formulation in which dermatologic drugs are delivered.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0011-4162
pubmed:author
pubmed:issnType
Print
pubmed:volume
77
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7-11
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
The rationale for advancing the formulation of azelaic acid vehicles.
pubmed:affiliation
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
pubmed:publicationType
Journal Article, Review